Cargando…
Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma
INTRODUCTION: Extrapolating long-term overall survival (OS) from shorter-term clinical trial data is key to health technology assessment in oncology. However, extrapolation using conventional methods is often subject to uncertainty. Using ciltacabtagene autoleucel (cilta-cel), a chimeric antigen rec...
Autores principales: | Palmer, Stephen, Lin, Yi, Martin, Thomas G., Jagannath, Sundar, Jakubowiak, Andrzej, Usmani, Saad Z., Buyukkaramikli, Nasuh, Phelps, Hilary, Slowik, Rafal, Pan, Feng, Valluri, Satish, Pacaud, Lida, Jackson, Graham |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447673/ https://www.ncbi.nlm.nih.gov/pubmed/37270762 http://dx.doi.org/10.1007/s40487-023-00230-x |
Ejemplares similares
-
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
por: Cohen, Adam D., et al.
Publicado: (2023) -
S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
por: Einsele, Hermann, et al.
Publicado: (2023) -
P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
por: van de Donk, N., et al.
Publicado: (2023) -
B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
por: Zweegman, S., et al.
Publicado: (2023) -
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma
por: Jagannath, Sundar, et al.
Publicado: (2023)